Citi raised the firm’s price target on Kymera Therapeutics (KYMR) to $80 from $60 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo
- Kymera Therapeutics: Promising Advancements and Strategic Collaborations Drive Buy Rating
- Kymera Therapeutics participates in a conference call with JPMorgan
- Kymera Therapeutics price target raised to $63 from $53 at Oppenheimer
- Kymera Therapeutics price target raised to $68 from $53 at Truist